Treatment of Relapsed or Refractory Multiple Myeloma With BCMA ...

BCMA-directed therapy for early relapsed and/or refractory multiple ...

BCMA-directed chimeric antigen receptor T cell therapies and bispecific T cell engagers are moving to earlier lines of therapy in multiple ...

Serial treatment of relapsed/refractory multiple myeloma with ...

Myeloma patients progressing on BCMA-targeted therapy can maintain BCMA expression and still respond to different BCMA-targeted therapy.

Salvage therapies including retreatment with BCMA-directed ...

For patients with relapsed/refractory multiple myeloma with a relapse after B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell therapy ( ...

CARVYKTI® is the First and Only BCMA-Targeted Treatment ...

“CARVYKTI demonstrated remarkable efficacy as a personalized, one-time infusion in the earlier treatment of relapsed/refractory multiple myeloma ...

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory ...

Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) ...

Treatment of Relapsed or Refractory Multiple Myeloma With BCMA ...

In this article, Dr Kumar discusses novel treatments for R/R MM, with a focus on BCMA and bispecific antibodies, and future directions for research.

Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple ...

The variability of surface receptors on myeloma cells provides new avenues for immune effector therapies in patients with anti-BCMA therapy- ...

Teclistamab in Relapsed or Refractory Multiple Myeloma

Patients had received a median of 5 previous lines of therapy (range, 2 to 14), and 116 (70.3%) had received at least two immunomodulatory agents, at least two ...

Elranatamab in relapsed or refractory multiple myeloma - Nature

Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, ...

The Gaining Momentum of BCMA-Directed Therapies for Relapsed ...

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma · Idecabtagene vicleucel: The first CAR T-cell therapy ...

Efficacy and safety of teclistamab in patients with relapsed/refractory ...

Key Points. Teclistamab provides clinically meaningful responses in patients with RRMM with prior anti-BCMA treatment.The safety profile of ...

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

In heavily treated patients with relapsed/refractory MM (RRMM), approved BCMA-targeted CAR-T therapies have shown overall response rates (ORRs) ...

Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory ...

Most multiple myeloma patients with relapsed/refractory disease will undergo CAR T-cell therapy targeting B-cell maturation antigen (BCMA), ...

Release Details - Investor Relations | Poseida Therapeutics, Inc.

"P-BCMA-ALLO1 is one of the most advanced allogeneic CAR-T in clinical development for multiple myeloma, manufactured using non-viral technology ...

Multiple myeloma: Treatment of second or later relapse - UpToDate

SUMMARY AND RECOMMENDATIONS · INTRODUCTION · ASSESS DRUG SENSITIVITY · NON-PENTA-REFRACTORY DISEASE · PENTA-REFRACTORY DISEASE · Targeting BCMA · - ...

Identification of potential resistance mechanisms and therapeutic ...

BCMA CAR-T is highly effective for relapsed/refractory multiple myeloma(R/R-MM) and significantly improves the survival of patients.

Corporate news details - Bristol Myers Squibb - Press Releases

... BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma. Download PDF Format (opens in new window). Abecma is a first-in-class ...

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory ...

Multiple myeloma remains an incurable plasma-cell cancer. Advancements in treatment, including the introduction of immunomodulatory drugs, ...

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T ...

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa ...

BCMA Therapies Changing Treatment in Relapsed/Refractory ...

That was one of the ways by which we could approach multiple myeloma therapeutics. The CAR T-cell therapies were the first to demonstrate not ...